Larvol Delta - SOLARA-A-Study-of-BH30643-in-Subjects-With-Locally-Advanced-or-Metastatic-NSCLC-Harboring-EGFR-andor-HER2-Mutations

BH-30643 - BlossomHill Therap

https://www.globenewswire.com/news-release/2026/08/18/3346704/0/en/blossomhill-therapeutics-announces-fda-fast-track-designation-for-bh-30643-a-macrocyclic-omni-egfr-inhibitor-for-the-treatment-of-advanced-egfr-c797s-positive-nsclc.html

Aug 18, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next